Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Phase 2

Terminated

Conditions: Colon Cancer
Rectal Cancer

Interventions: Drug: MK-2206

First Posted Date: 2010-08-23

Last Posted Date: 2015-11-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT01186705

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Progressive Stretching
Behavioral: Linear Aerobic Training
Behavioral: Nonlinear Aerobic Training
Other: Cardiopulmonary exercise test (CPET)
Other: Blood draws

First Posted Date: 2010-08-23

Last Posted Date: 2025-02-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 174

Registration Number: NCT01186367

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Phase 2

Terminated

Conditions: Neuroblastoma

Interventions: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid

First Posted Date: 2010-08-18

Last Posted Date: 2019-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 46

Registration Number: NCT01183884

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic

First Posted Date: 2010-08-18

Last Posted Date: 2019-08-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 31

Registration Number: NCT01183897

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Drug: 3F8 and 13-cis-retinoic acid

First Posted Date: 2010-08-17

Last Posted Date: 2019-08-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01183429

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Pralatrexate With Vitamin B12 and Folic Acid

First Posted Date: 2010-08-17

Last Posted Date: 2015-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT01183065

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States

and more 2 locations

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Drug: 3F8 monoclonal antibody and 13-cis-Retinoic Acid

First Posted Date: 2010-08-17

Last Posted Date: 2019-10-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT01183416

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

Phase 1

Completed

Conditions: Bladder Cancer
Renal Pelvis Cancer
Ureter Cancer

Interventions: Drug: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)

First Posted Date: 2010-08-16

Last Posted Date: 2016-03-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT01182168

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Rehabilitation of Cognitive Changes in Breast Cancer Survivors

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: Cogmed Working Memory Training Program

First Posted Date: 2010-08-16

Last Posted Date: 2023-09-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT01182506

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Lung Inflammation and Lung Metastases From Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Behavioral: questionnaire, blood draw and urine sample

First Posted Date: 2010-08-16

Last Posted Date: 2016-07-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 400

Registration Number: NCT01182519

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy